May 4th, 2023, Shanghai, China – Rona Therapeutics, Inc. (" Rona ") announced the appointment of Dr. Hongmei Li as Chief Medical Officer (CMO) of the company. Dr. Hongmei Li will be responsible for the establishment of clinical team and related business, as well as assisting the company's strategic business development, to accelerate the process of global multi-center clinical trials and new products to market. As a member of the company's management, Dr. Li reports directly to Ms. Stella SHI, Chief Executive Officer (CEO) of Rona Therapeutics.

Dr. Hongmei Li has nearly 20 years of experience in drug development from research to clinical stage in academic and multinational pharmaceutical companies. Prior to joining Rona, she was Senior Investment Director of Venture Fund at Boehringer Ingelheim (BI), where she was involved in global Biotech investment evaluation also incubation and post-investment management in Asia Pacific. During up to 15 years’ experience in clinical development, she has successively served as Clinical Research Physician, Therapeutic area (TA) Head of Metabolic and Immunology in Bristol-Myers Squibb (BMS) China R&D Center, TA head of Infectious and Vaccine in Johnson & Johnson (J&J) China R&D Center, Early Development Head in J&J Asia R&D Center, Head of Clinical Development in BI Greater China, to lead and involve into clinical development and approval of more than 10 novel drugs with more than 20 indications in China and Asia Pacific; before joining the industry, she was an Assistant Reseacher in Shanghai Institute of Materia Medica, Chinese Academy of Sciences.

Dr. Li holds a M.D. in Internal Medicine from Tongji University Medical School, and a Ph.D. in Genetics from Fudan University, which was co-trained with Duke University in USA.

Ms. Stella SHI, CEO of Rona Therapeutics said, "We warmly welcome Dr. Hongmei Li to the management team of Rona Therapeutics. Dr. Li has extensive experience and outstanding leadership in drug development, especially clinical research, and development. Her expertise and international vision will help Rona to accelerate the development of multi-center clinical trials and the early approval of new products. "

Dr. Hongmei Li said, "I am very pleased to join Rona Therapeutics. The company's technological breakthroughs in the field of oligonucleotide drug research and development and the world's leading pipeline layout are exciting. I look forward to working with the team to advance the nucleic acid drug research and development pipeline to the clinic and market faster and better, to benefit patients around the world."

Rona Therapeutics is a pioneering RNA therapeutics platform company dedicated to discovery and development of modular and programmable RNA medicines to deliver to patients around the world.

Backed by blue-chip investors, Rona has developed proprietary RAZOR™ platform to discover differentiated siRNA therapeutics from next-generation chemical modification and novel biological insights. Together with partners, Rona is dedicated to advancing transformative RNA therapeutics into clinic in metabolic syndrome, glomerulonephritis, CNS and ocular diseases. For more information, please visit www.ronatherapeutics.com.